

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

Vitamin D Testing

Policy Number: AHS – G2005 – Vitamin D Testing	Prior Policy Name and Number, as applicable:
Original Effective Date: 6/01/2022	
Current Effective Date: 6/01/2022	

I. Policy Description

Vitamin D is a precursor to steroid hormones and plays a key role in calcium absorption and mineral metabolism. Vitamin D promotes enterocyte differentiation and the intestinal absorption of calcium. Other effects include a lesser stimulation of intestinal phosphate absorption, suppression of parathyroid hormone (PTH) release, regulation of osteoblast function, osteoclast activation, and bone resorption (Pazirandeh & Burns, 2021).

Vitamin D is present in nature in two major forms. Ergocalciferol, or vitamin D2, is found in fatty fish (e.g., salmon and tuna) and egg yolks, although very few foods naturally contain significant amounts of vitamin D. Cholecalciferol, or vitamin D3, is synthesized in the skin via exposure to ultraviolet radiation present in sunlight. Some foods are also fortified with vitamin D, most notably milk and cereals (Sahota, 2014).

Major risk factors for vitamin D deficiency include inadequate sunlight exposure, inadequate dietary intake of vitamin D-containing foods, and malabsorption syndromes, such as Crohn’s disease and celiac disease (Dedeoglu, Garip, & Bodur, 2014). “The risk of vitamin D deficiency differ[s] by age, sex, and race and ethnicity (Looker et al., 2011).”

II. Related Policies

Policy Number	Policy Title
AHS-G2164	Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

1. 25-hydroxyvitamin D serum testing **MEETS COVERAGE CRITERIA** in individuals with an underlying disease or condition which is specifically associated with vitamin D deficiency or decreased bone density (see Guideline 1 below).
2. Testing for D2 and D3 fractions of 25-hydroxyvitamin D **MEETS COVERAGE CRITERIA** as part of the total 25-hydroxyvitamin D analysis.
3. Repeat testing for serum 25-hydroxyvitamin D **MEETS COVERAGE CRITERIA** in individuals who have documented vitamin D deficiency, at least 12 weeks after initiation of vitamin D supplementation therapy.
 - a. Repeat testing for monitoring of supplementation therapy should not exceed 4 testing instances per year until the therapeutic goal is achieved.
 - b. Once therapeutic range has been reached, annual testing, meets coverage criteria.
4. 1,25-dihydroxyvitamin D serum testing **MEETS COVERAGE CRITERIA** in the evaluation or treatment of conditions that are associated with defects in vitamin D metabolism (see Guideline 2 below).
5. The following testing **DOES NOT MEET COVERAGE CRITERIA**:
 - a. 1,25-dihydroxyvitamin D serum testing for testing and screening of vitamin D deficiency.
 - b. Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals and/or during general encounters

Guideline 1: Indications that support coverage criteria for serum measurement of 25-hydroxyvitamin D are as follows:

- A. Biliary cirrhosis and other specified disorders of the biliary tract
- B. Blind loop syndrome
- C. Celiac Disease
- D. Coronary artery disease in individuals where risk of disease progression is being considered against benefits of chronic vitamin D and calcium therapy
- E. Dermatomyositis
- F. Eating disorders
- G. Hypercalcemia, hypocalcemia or other disorders of calcium metabolism

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

- H. Hyperparathyroidism or hypoparathyroidism
- I. Hypervitaminosis of vitamin D
- J. Individuals receiving hyperalimentation
- K. Intestinal malabsorption
- L. Liver cirrhosis
- M. Long term use of anticonvulsants, glucocorticoids and other medications known to lower vitamin D levels
- N. Malnutrition
- O. Myalgia and other myositis not specified
- P. Myopathy related to endocrine diseases
- Q. Neoplastic hematologic disorders
- R. Obesity
- S. Osteogenesis imperfecta
- T. Osteomalacia
- U. Osteopetrosis
- V. Osteoporosis
- W. Pancreatic steatorrhea
- X. Primary or miliary tuberculosis
- Y. Psoriasis
- Z. Regional enteritis
- AA. Renal, ureteral or urinary calculus
- BB. Rickets
- CC. Sarcoidosis
- DD. Stage III-V Chronic Kidney Disease and End Stage Renal Disease

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

EE. Systemic lupus erythematosus

Guideline 2: Indications that support medical necessity for serum testing of 1,25-dihydroxyvitamin D are as follows:

- A. Disorders of calcium metabolism
- B. Familial hypophosphatemia
- C. Fanconi syndrome
- D. Hyperparathyroidism or hypoparathyroidism
- E. Individuals receiving hyperalimentation
- F. Neonatal hypocalcemia
- G. Osteogenesis imperfecta
- H. Osteomalacia
- I. Osteopetrosis
- J. Primary or miliary tuberculosis
- K. Renal, ureteral or urinary calculus
- L. Rickets
- M. Sarcoidosis
- N. Stage III-V Chronic Kidney Disease and End Stage Renal Disease

IV. Scientific Background

Vitamin D is an important nutrient that helps the body absorb calcium and maintain adequate bone strength. In order to be used in the metabolic process, vitamin D that is consumed or formed in the skin must first be activated via the addition of hydroxyl groups. Two forms of activated vitamin D are found in human circulation: 25-hydroxyvitamin D (calcidiol or 25OHD) and 1,25-dihydroxyvitamin D (calcitriol). 25-hydroxyvitamin D is the predominant and most stable form, but 1,25-dihydroxyvitamin D is the metabolically active form. The initial activation step occurs in the liver, where 25OHD is synthesized, and the second hydroxyl group is added in the kidney, creating the fully activated 1,25-dihydroxy form (Sahota, 2014).

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

25OHD has a half-life of 15 days in the circulation, whereas 1,25-dihydroxyvitamin D has a much shorter circulating half-life of 15 hours. Consequently, measurement of serum 25OHD is generally accepted as the preferred test to evaluate an individual's vitamin D status despite lack of standardization between methods and laboratories (Glendenning & Inderjeeth, 2012; Sahota, 2014; Scott et al., 2015).

Vitamin D deficiency typically is defined as a serum 25OHD level less than 20 ng/ml, and certain organizations consider <30 ng/ml as insufficient. Trials of vitamin D supplementation (Chapuy et al., 2002; Dawson-Hughes, Harris, Krall, & Dallal, 1997; Sanders et al., 2010; Trivedi, Doll, & Khaw, 2003) and the Institute of Medicine (IOM) systematic review (Ross et al., 2011) recommend maintaining the serum 25OHD concentration between 20 and 40 ng/mL (50 to 100 nmol/L), whereas other experts favor maintaining 25OHD levels between 30 and 50 ng/mL (75 to 125 nmol/L). Experts agree that levels lower than 20 ng/mL are suboptimal for skeletal health. The optimal serum 25OHD concentrations for extra-skeletal health have not been established (Bess Dawson-Hughes, 2021). Approximately 15% of the U.S. pediatric population suffers from either vitamin D deficiency or insufficiency. Limited sun exposure and the use of sunscreen compromises production of vitamin D, contributing to low 25OHD levels. "UVB absorption is blocked by artificial sunscreens, and sunscreens with a sun protection factor (SPF) of 30 can decrease vitamin D synthetic capacity by as much as 95 percent" (Madhusmita, 2020). Also, "vitamin D deficiency has been reported in dark-skinned immigrants from warm climates to cold climates in North America and Europe" (B. Dawson-Hughes, 2021). For example, a study by Awumey and colleagues found that Asian Indians who immigrated to the U.S. were considered vitamin D insufficient or deficient even after the administration of 25OHD. "Thus, Asian Indians residing in the U.S. are at risk for developing vitamin D deficiency, rickets, and osteomalacia" (Awumey, Mitra, Hollis, Kumar, & Bell, 1998).

Vitamin D deficiency has been associated with important short- and long-term health effects, such as rickets, osteomalacia, and the risk of osteoporosis (Sahota, 2014). Rickets in children can result in skeletal deformities. To prevent nutritional rickets in infants, vitamin D supplementation is recommended at 400 IU/day; personalized dosages are possible and would require 25OHD testing (Zittermann, Pilz, & Berthold, 2019). In adults, osteomalacia can result in muscular weakness, bone weakness, and osteoporosis which leads to an increased risk for falls and fractures (Granado-Lorencio, Blanco-Navarro, & Perez-Sacristan, 2016).

A role for vitamin D has been suggested in several other conditions and metabolic processes including, but not limited to, cancer, cardiovascular disease, hypertension, diabetes, and preeclampsia. While vitamin D insufficiency has been associated with several cancer types, inconsistencies cause discrepancies in suggested treatment methods; currently, no official institutional guidelines recommend a dietary vitamin D supplementation for cancer prevention (McNamara & Rosenberger, 2019). 25-hydroxyvitamin D (25OHD) is the accepted biomarker of circulating vitamin D, and in utilization of this biomarker, researchers have reported an association between a high vitamin D production rate and a lowered risk of colorectal cancer

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

(Weinstein et al., 2015). Further, low concentrations of 25OHD have been associated with a high risk of cardiovascular disease and mortality, suggesting that patients deficient in vitamin D have an increased risk in developing cardiovascular disease (Crowe et al., 2019). However, conclusive evidence for the role of vitamin D in these conditions is not available (Aspray et al., 2014; Ross et al., 2011). Based on controversial evidence, researchers continue to emphasize the fact that vitamin D supplementation is not an accepted prevention method for cardiac events or cancer (Ebell, 2019).

Certain other conditions may impact an individual's ability to absorb or activate vitamin D, thereby resulting in vitamin D deficiency. These include, but are not limited to, celiac disease, liver cirrhosis, chronic kidney disease, and bariatric surgery. Since Vitamin D is fat soluble, any impact on fat absorption or storage may have an effect on circulating vitamin D levels (B. Dawson-Hughes, 2021).

According to the Institute of Medicine (IOM), routine dietary supplementation with vitamin D is recommended for most individuals. While there are no differences in regard to gender and recommended daily dose of vitamin D, there are differences depending on age. The IOM recommends a dietary allowance of 600 IU for individuals up to 70 years old, and 800 IU for individuals older than 70 (Ross et al., 2011), although these recommendations have been met with some criticism as being too low to adequately impact vitamin D levels in some individuals. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures in noninstitutionalized postmenopausal women (Moyer, 2013).

Vitamin D toxicity is very rare and occurs only when levels of 25OHD are >500 nmol/L [>200 ng/mL], which is well above the level considered sufficient. Vitamin D toxicity may cause hypercalciuria, hypercalcemia, renal stones, and renal calcification with renal failure (Moyer, 2013). Additional research suggests that excess 25-hydroxyvitamin D3 aggravates tubulointerstitial injury (Kusunoki et al., 2015).

Insource Diagnostics has developed two similar quantitative laboratory developed tests (LDTs) termed Sensieva Vena™ 25OH Vitamin D2/D3 and Droplet 25OH Vitamin D2/D3 (InSourceDx, 2019a, 2019b). These assays utilize liquid chromatography coupled with mass spectrometry (LC/MS/MS) to measure both D2 and D3. The LC/MS/MS assessment technique is the apparent gold standard for vitamin D2 and D3 measurement, and is the only currently available method to measure both vitamins individually (InSourceDx, 2019b). These assays may assist in the measurement of several ailments related to abnormal vitamin D levels including parathyroid function, dietary absorption, calcium metabolism, and vitamin D treatment effectiveness; serum, plasma and blood microsamples can be utilized for these tests (InSourceDx, 2019a). The 20uL serum/plasma method of the Sensieva™ 25OH Vitamin D2/D3 LDT was approved by the CDC's VDSCP in 2017-2018 (CDC, 2019). This test is no longer certified by the CDC's VDSCP and as of May 2020 Insource Diagnostics website has been removed. Therefore, it is unclear if this test is still available.

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

Analytical Validity

Serum or plasma concentration of 25OHD can be measured using a number of assays, including ELISA, radioimmunoassay (RIA), mass spectrometry, and HPLC. Assays using LC-MS/MS can differentiate between D2 and D3. These methods “can individually quantitate and report both analytes, in addition to providing a total 25-hydroxyvitamin D concentration” (Krasowski, 2011). RIA-based assays for 25OHD can have intra- and inter-assay variations of 8 – 15%, and the Immunodiagnostic Systems (IDS)-developed RIA has a reported 100% specificity for D3 and 75% for D2 (Holick, 2009). “For most HPLC and LC-MS/MS methods extraction and procedural losses are corrected for by the inclusion of an internal standard which, in part, may account for higher results compared to immunoassay” (Wallace, Gibson, de la Hunty, Lamberg-Allardt, & Ashwell, 2010). Even though LC-MS/MS is considered to be the gold standard of measuring 25OHD and its metabolites, only approximately 20% of labs report using it (Avenell, Bolland, & Grey, 2018). One study reports that 46% of samples measured using LC-MS/MS were classified as vitamin D-deficient whereas, when the samples were measured using an immunoassay method, 69% were vitamin D-deficient (<30 nmol/L) (Annema, Nowak, von Eckardstein, & Saleh, 2018).

The Centers for Disease Control and Prevention (CDC) have developed a vitamin D standardization certification program (VDSCP). This program helps to ensure that all LDT vitamin D tests are accurate and reliable by evaluating the performance and overall reliability of these assessments over time, supplying reference measurements for both 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, and providing technical support to additional programs and studies (CDC, 2017b).

Due to the great variability among the different assays used to measure vitamin D levels, the VDSCP was created. Interassay variability yields an inadequate basis to establish if 25OHD increases or decreases the risk of non-skeletal diseases and hampers the development of evidence-based guidelines and policies (Sempos & Binkley, 2020). VDSCP studies can either be retrospective or prospective; therefore, standardization of national nutrition survey data may be performed. For example, it was originally thought, based on reports from the National Health and Nutrition Examination Surveys (NHANES), that there had been a dramatic decline in mean 25OHD levels in the US population from 1990 to the period 2001–2004. DiaSorin Radioimmunoassay was used to measure 25OHD levels in these surveys. However, after standardizing the results using VDSCP methods, it was found that the mean 25OHD levels were stable from 1990-2004 (Sempos et al., 2018). The VDSCP program established four steps to achieve standardization, as described by :

1. “Fit for use...means that assay chosen will perform appropriately and provide standardised measurements in the patient/study populations in the conditions for which it will be used...[as] some immunoassays do not function appropriately in all patient populations.

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

2. [Assay is] Certified by the CDC Vitamin D Standardization Certification Program as being standardised and having an appropriate measurement range or be a documented standardised laboratory-developed HPLC or LC-MS/MS assay with an appropriate measurement range...see which ones are currently, or have been in the past, certified by the CDC as meeting VDSP performance criteria of having a total (coefficient of variation) $CV \leq 10\%$ and a mean bias with the range of -5 to $+5\%$... VDSP recommends using an assay that does have an appropriate measurement range for the population it will be used in; for example, it should be able to measure 25(OH)D in persons who are deficient.
3. Appropriate level of assay precision and accuracy...it has been recommended that a standardised LC-MS/MS assay be selected.
4. [The assay] Meets VDSP assay standardisation criteria in your ‘hands’ or laboratory.... We recommend a testing period in order to verify that an immunoassay is standardized especially since there is generally very little an individual laboratory can do to ‘calibrate’ an immunoassay” (Sempos & Binkley, 2020).

Clinical Validity and Utility

A retrospective study of 32,363 tests of serum 25OHD found that a significant proportion of the lab requests were unjustified by medical criteria, and “that clinical and biochemical criteria may be necessary to justify vitamin D testing but not sufficient to indicate the presence of vitamin D deficiency” (Granado-Lorencio et al., 2016).

The table below lists the criteria used for vitamin D testing in the study by Granado and colleagues. (Granado-Lorencio et al., 2016).

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

Clinical conditions

- Differential diagnosis (i.e. hypercalcemia)
- Undernourished subjects
- Malabsorption syndromes (i.e. celiac disease, Chron’s disease, radiation enteritis)
- Eating disorders (i.e. morbid obesity, anorexia and bulimia)
- Candidates for bariatric surgery
- Conditions associated with altered calcium, phosphorus or vitamin D metabolism (i.e. osteoporosis, rickets, renal disease, liver failure, multiple mieloma, sarcoidosis, hyper/hypoparathyroidism, liver and kidney transplants)
- Diseases related to low or null sun exposure (i.e. lupus, porphyria)
- Vitamin D-related inborn errors of metabolism

Therapeutic criteria

- Pharmacotherapy associated with increased vitamin D catabolism (i.e. antiseizure drugs, glucocorticoids)
- Treatment for AIDS and tuberculosis
- Monitorization of vitamin D treatment

Biochemical indicators

- Alterations of serum or urine levels of calcium and phosphorus
 - Elevation of alkaline phosphatase (in the absence of altered liver enzymes or growth)
 - Serum levels of parathyroid hormone out of the reference range (14–72 pg/mL)
 - Previous (<6 months) serum values of 25-OH-vitamin D out of the reference interval (<37.5 or >160 nmol/L)
-

A meta-analysis study by Bolland and colleagues of 81 randomized controlled trials with a combined total of 53,537 participants measured the effects, if any, vitamin D supplementation had on fractures, falls, and bone density. They found that there was no clinically relevant difference in bone mineral density at any site between the control and experimental groups; moreover, “for total fracture and falls, the effect estimate lay within the futility boundary for relative risks of 15%, 10%, 7.5%, and 5% (total fracture only), suggesting that vitamin D supplementation does not reduce fractures or falls by these amounts. Our findings suggest that vitamin D supplementation does not prevent fractures or falls or clinically meaningful effects on bone mineral density. There were no differences between the effects of higher and lower doses of vitamin D. There is little justification to use vitamin D supplements to maintain or improve musculoskeletal health. This conclusion should be reflected in clinical guidelines” (Bolland, Grey, & Avenell, 2018).

A prospective study by Hao and colleagues aims to determine whether 25OHD levels is associated with mortality or the ability to walk in a patient cohort after hip fracture surgery. Each year, 300,000 elderly patients, 75% who are women, are hospitalized for hip fractures (CDC, 2017a). In this study, 290 elderly patients with hip fractures were included, in which patients with 25OHD deficiency (<12 ng/ml) were used as the reference group. They observed a 56–64% increased rate of walking in patients who had 25OHD levels > 12 ng/ml at 30 days and 60 days after hip fracture surgery compared with 35% for patients able to walk 30 days postoperatively who had 25OHD levels < 12 ng/ml (Hao, Carson, Schluskel, Noveck, & Shapses, 2020) . It is important to note that only the preoperative 25OHD levels accurately reflect the patient’s ability to walk after 30 days, and the postoperative vitamin D status is not related and should not be used to determine clinical or nutritional interventions. Holick (2020) releases a call for action, discussing the data collected by Hao, to establish guidelines which will assess vitamin D status as needed for patients with hip fracture. Holick suggests that

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

“patients aged ≥ 50 y presenting with fractures, especially those with hip fracture, should be evaluated at intake for their vitamin D status. Consideration should be made to provide vitamin D supplementation if dietary/supplemental intake or blood concentrations of 25(OH)D suggest deficiency” (Holick, 2020).

Another randomized clinical trial administered a monthly high-dose of vitamin D to 5,108 participants in order to determine if a relationship exists between increased vitamin D levels and cardiovascular disease prevention. This double-blind trial was placebo-controlled; participants were given an initial dose of 200,000 IU of vitamin D, and then each month after for a range of 2.5-4.2 years were given 100,000 IU of vitamin D (Scragg et al., 2017). Results showed that in a random sample of 438 participants, cardiovascular disease occurred in 11.8% of patients who received vitamin D supplements and in 11.5% of patients who received placebos. This suggests that vitamin D administration does not prevent cardiovascular disease and should not be used for this purpose (Scragg et al., 2017).

Regarding pregnancy, vitamin D deficiency is common around the world and threatens fetal health and growth. Results from 203 Indonesian women who were followed from their first trimester of pregnancy until delivery showed astronomical vitamin D deficiency rates at approximately 75% (Yuniati et al., 2019). Data collected from these women included maternal demography, bloodwork to test ferritin levels, 25(OH) vitamin D results in their first trimester, and the final birthweight of the child after delivery. Final results did not show any association between ferritin, hemoglobin level, and vitamin D in either the first trimester of pregnancy or in the final birthweight of the neonates after delivery; however, the authors suggest that other unknown variables may be important and that nutritional supplementation during pregnancy is still vital (Yuniati et al., 2019).

Research has also been conducted on the association of 25(OH)D levels and SARS-CoV-2 infection. Ribeiro et al. (2021) conducted a retrospective cohort study on 1638 patients tested for SARS-CoV-2 infection and found that “previous insufficient 25(OH)D ($<30\text{ng/mL}$) concentration and high total cholesterol were associated with SARS-CoV-2 infection among adults >48 y in the study population.” This may be attributable to the role that vitamin D serves in the immune system and its anti-viral activity through autophagy, as well as its high expression in cells of the lungs, thus rendering those with lower levels of 25(OH)D more susceptible to infection without these defenses (Ul Afshan, Nissar, Chowdri, & Ganai, 2021).

On the other hand, Javed et al. (2020) found that “high serum levels of vitamin D are associated with a lower risk of incidence and progression of [colorectal cancer].” This could make vitamin D testing crucial to identify possible future therapeutic modalities for patients with both low serum vitamin D and colorectal cancer. Like its mechanisms that hinder SARS-CoV-2 infection, such as being pro-apoptotic and anti-inflammatory, vitamin D has been shown to “decrease growth and differentiation of colon epithelial cells.” With more large-scale human trials, testing and treatment using vitamin D can become more widely applicable.

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

V. Guidelines and Recommendations

The Endocrine Society (Holick et al., 2011)

The Endocrine Society recommends serum testing of 25-hydroxyvitamin D for evaluation of vitamin D status in individuals who are at risk of deficiency, including those with osteoporosis, obesity, or a history of falls. 1,25-dihydroxyvitamin D testing is not recommended for screening of at-risk individuals, due to its very short half-life in circulation, but is recommended for a few conditions in which formation of the 1,25-dihydroxy form may be impaired (Holick et al., 2011).

Institute of Medicine (Ross et al., 2011)

After an extensive evaluation of published studies and testimony from investigators, the Institute of Medicine determined that supplementation with vitamin D is appropriate; however, guidelines regarding the use of serum markers of vitamin D status for medical management of individual patients and for screening were beyond the scope of the Committee's charge, and evidence-based consensus guidelines are not available (Ross et al., 2011).

National Osteoporosis Society (Aspray et al., 2014)

The National Osteoporosis Society recommends the measurement of serum 25 (OH) vitamin D (25OHD) to estimate vitamin D status in the following clinical scenarios: bone diseases that may be improved with vitamin D treatment; bone diseases, prior to specific treatment where correcting vitamin D deficiency is appropriate; musculoskeletal symptoms that could be attributed to vitamin D deficiency. The guideline also states that routine vitamin D testing is unnecessary where vitamin D supplementation with an oral antiresorptive treatment is already planned and sets the following serum 25OHD thresholds: <30 nmol/l is deficient; 30-50 nmol/l may be inadequate in some people; >50 nmol/l is sufficient for almost the whole population (Aspray et al., 2014).

American College of Obstetricians and Gynecologists (ACOG) Gynecologic Care for Adolescents and Young Women With Eating Disorders (Wassenaar, O'Melia, & Mehler, 2018) (reaffirmed 2020)

ACOG has stated that in patients with low bone mineral density (BMD), "appropriate calcium (1,000–1,300 mg per day) and vitamin D (600 international units/day) intake can be recommended; however, there is no evidence that vitamin supplementation improves BMD. A patient's 25-hydroxy vitamin D level should be checked and, if less than 30 ng per mL, the patient should be given supplementation for 6–8 weeks in the form of 2,000 international units daily or 50,000 international units weekly (Wassenaar et al., 2018)."

United States Preventive Services Task Force (Moyer & USPSTF, 2013; USPSTF, 2018, 2021)

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

The USPSTF recently issued the guideline *Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults*, which recommends the following:

“The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of vitamin D and calcium supplementation, alone or combined, for the primary prevention of fractures in community-dwelling, asymptomatic men and premenopausal women. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of daily supplementation with doses greater than 400 IU of vitamin D and greater than 1000 mg of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women. (I statement) The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1000 mg or less of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women. (D recommendation) These recommendations do not apply to persons with a history of osteoporotic fractures, increased risk for falls, or a diagnosis of osteoporosis or vitamin D deficiency” (USPSTF, 2018).

In the 2013 update to the USPSTF recommendation concerning the use of vitamins for the primary prevention of cardiovascular disease and cancer, they concluded that there was insufficient evidence to assess the efficacy of multivitamins, including those containing vitamin D, in the prevention of cardiovascular disease or cancer (Moyer & USPSTF, 2013). This guideline is currently undergoing review as of April 27, 2021.

The USPSTF published their recommendation concerning screening of vitamin D deficiency in asymptomatic community-dwelling, nonpregnant adults in 2021. “The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic adults” (I statement) (USPSTF, 2021).

American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery (Mechanick et al., 2019; Mechanick et al., 2013)

“Baseline and annual postoperative evaluation for vitamin D deficiency is recommended after Rouxen-Y gastric bypass (RYGB), sleeve gastrectomy, or biliopancreatic diversion without/with duodenal switch (BPD/ DS)” (Mechanick et al., 2019). Minimal daily nutritional supplementation for patients with Rouxen-Y gastric bypass (RYGB) and Lennox-Gastaut syndrome (LSG) all in chewable form initially should be at least 3000 international units of vitamin D (titrated to therapeutic 25-hydroxyvitamin D levels >30 ng/ml). Minimal daily nutritional supplementation for patients with Laparoscopic adjustable gastric banding (LAGB) should include at least 3000 international units of vitamin D (titrated to therapeutic 25-dihydroxyvitamin D levels). Patients with severe vitamin D malabsorption are recommended initial oral doses of vitamin D2 (50,000 IU 1 to 3 times/weekly) or D3 (minimum of 3,000 IU/day to 6,000 IU/day) (Mechanick et al., 2019).

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

American Academy of Pediatrics (Golden & Abrams, 2014)

“Evidence is insufficient to recommend universal screening for vitamin D deficiency... In the absence of evidence supporting the role of screening healthy individuals at risk for vitamin D deficiency in reducing fracture risk and the potential costs involved, the present AAP report advises screening for vitamin D deficiency only in children and adolescents with conditions associated with reduced bone mass and/or recurrent low-impact fractures. More evidence is needed before recommendations can be made regarding screening of healthy black and Hispanic children or children with obesity. The recommended screening is measuring serum 25-OH-D concentration, and it is important to be sure this test is chosen instead of measurement of the 1,25-OH₂-D concentration, which has little, if any, predictive value related to bone health” (Golden & Abrams, 2014).

American College of Obstetricians and Gynecologists (ACOG, 2011) (reaffirmed in 2021)

“At this time, there is insufficient evidence to support a recommendation for screening all pregnant women for vitamin D deficiency. For pregnant women thought to be at increased risk of vitamin D deficiency, maternal serum 25-hydroxyvitamin D levels can be considered and should be interpreted in the context of the individual clinical circumstance” (ACOG, 2011).

VI. State and Federal Regulations, as applicable

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g. Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. For the most up-to-date Medicaid policies and coverage, please visit the applicable state Medicaid website.

A search of the FDA Device database on September 30, 2021 for “vitamin D” yielded 42 results. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

VII. Applicable CPT/HCPCS Procedure Codes

Code Number	Code Description
-------------	------------------

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

82306	Vitamin D; 25 hydroxy
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative Proprietary test: Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay Lab/Manufacturer: InSource Diagnostics

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

VIII. Evidence-based Scientific References

- ACOG. (2011). ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol*, 118(1), 197-198.
doi:10.1097/AOG.0b013e318227f06b
- Annema, W., Nowak, A., von Eckardstein, A., & Saleh, L. (2018). Evaluation of the new restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient and vitamin D-supplemented individuals. *J Clin Lab Anal*, 32(4), e22328.
doi:10.1002/jcla.22328
- Aspray, T. J., Bowring, C., Fraser, W., Gittoes, N., Javaid, M. K., Macdonald, H., . . . Francis, R. M. (2014). National Osteoporosis Society vitamin D guideline summary. *Age Ageing*, 43(5), 592-595. doi:10.1093/ageing/afu093
- Avenell, A., Bolland, M. J., & Grey, A. (2018). 25-Hydroxyvitamin D - Should labs be measuring it? *Ann Clin Biochem*, 4563218796858. doi:10.1177/0004563218796858
- Awumey, E. M., Mitra, D. A., Hollis, B. W., Kumar, R., & Bell, N. H. (1998). Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. *J Clin Endocrinol Metab*, 83(1), 169-173. doi:10.1210/jcem.83.1.4514
- Bolland, M. J., Grey, A., & Avenell, A. (2018). Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *Lancet Diabetes Endocrinol*. doi:10.1016/s2213-8587(18)30265-1
- CDC. (2017a). Home and recreational safety: important facts about falls. Retrieved from <https://www.cdc.gov/homeandrecreationalafety/falls/>
- CDC. (2017b). VDSCP: Vitamin D Standardization-Certification Program. Retrieved from VDSCP: Vitamin D Standardization-Certification Program

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

- CDC. (2019). CDC Vitamin D Standardization-Certification Program. Retrieved from https://www.cdc.gov/labstandards/pdf/hs/CDC_Certified_Vitamin_D_Procedures-508.pdf
- Chapuy, M. C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., . . . Meunier, P. J. (2002). Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. *Osteoporos Int*, *13*(3), 257-264. doi:10.1007/s001980200023
- Crowe, F. L., Thayakaran, R., Gittoes, N., Hewison, M., Thomas, G. N., Scragg, R., & Nirantharakumar, K. (2019). Non-linear associations of 25-hydroxyvitamin D concentrations with risk of cardiovascular disease and all-cause mortality: Results from The Health Improvement Network (THIN) database. *J Steroid Biochem Mol Biol*, *195*, 105480. doi:10.1016/j.jsbmb.2019.105480
- Dawson-Hughes, B. (2021, July 6). Causes of vitamin D deficiency and resistance. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/causes-of-vitamin-d-deficiency-and-resistance>
- Dawson-Hughes, B. (2021, September 20). Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment>
- Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med*, *337*(10), 670-676. doi:10.1056/nejm199709043371003
- Dedeoglu, M., Garip, Y., & Bodur, H. (2014). Osteomalacia in Crohn's disease. *Arch Osteoporos*, *9*, 177. doi:10.1007/s11657-014-0177-0
- Ebell, M. H. (2019). Vitamin D Is Not Effective as Primary Prevention of Cardiovascular Disease or Cancer. *Am Fam Physician*, *100*(6), 374.
- Glendenning, P., & Inderjeeth, C. A. (2012). Vitamin D: methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment. *Clin Biochem*, *45*(12), 901-906. doi:10.1016/j.clinbiochem.2012.04.002
- Golden, N. H., & Abrams, S. A. (2014). Optimizing bone health in children and adolescents. *Pediatrics*, *134*(4), e1229-1243. doi:10.1542/peds.2014-2173
- Granado-Lorencio, F., Blanco-Navarro, I., & Perez-Sacristan, B. (2016). Criteria of adequacy for vitamin D testing and prevalence of deficiency in clinical practice. *Clin Chem Lab Med*, *54*(5), 791-798. doi:10.1515/cclm-2015-0781
- Hao, L., Carson, J. L., Schluskel, Y., Noveck, H., & Shapses, S. A. (2020). Vitamin D deficiency is associated with reduced mobility after hip fracture surgery: a prospective study. *The American Journal of Clinical Nutrition*, *112*(3), 613-618. doi:10.1093/ajcn/nqaa029
- Holick, M. F. (2009). Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol*, *19*(2), 73-78. doi:10.1016/j.annepidem.2007.12.001
- Holick, M. F. (2020). A call for action: standard of care guidelines to assess vitamin D status are needed for patients with hip fracture. *Am J Clin Nutr*, *112*(3), 507-509. doi:10.1093/ajcn/nqaa202

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., . . . Weaver, C. M. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 96(7), 1911-1930. doi:10.1210/jc.2011-0385

InSourceDx. (2019a). 25OH Vitamin D2/D3 - Droplet. Retrieved from https://insourcedx.com/ISD/demo2/services/blood/testmenu/droplet_tests/25OH-Vitamin-D2-D3

InSourceDx. (2019b). 25OH Vitamin D2/D3 - Sensieva Vena

Retrieved from

https://insourcedx.com/ISD/demo2/services/blood/testmenu/VENA_individual/25OH_Vitamin_D2-D3

Javed, M., Althwanay, A., Ahsan, F., Oliveri, F., Goud, H. K., Mehkari, Z., . . . Rutkofsky, I. H. (2020). Role of Vitamin D in Colorectal Cancer: A Holistic Approach and Review of the Clinical Utility. *Cureus*, 12(9), e10734-e10734. doi:10.7759/cureus.10734

Krasowski, M. D. (2011). Pathology Consultation on Vitamin D Testing. *American Journal of Clinical Pathology* 136(4), 507-514.

Kusunoki, Y., Matsui, I., Hamano, T., Shimomura, A., Mori, D., Yonemoto, S., . . . Rakugi, H. (2015). Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. *Kidney Int*, 88(5), 1013-1029. doi:10.1038/ki.2015.210

Looker, A. C., Johnson, C. L., Lacher, D. A., Pfeiffer, C. M., Schleicher, R. L., & Sempos, C. T. (2011). Vitamin D status: United States, 2001-2006. *NCHS Data Brief*(59), 1-8.

Madhusmita, M. (2020, June 22). Vitamin D insufficiency and deficiency in children and adolescents. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/vitamin-d-insufficiency-and-deficiency-in-children-and-adolescents>

McNamara, M., & Rosenberger, K. D. (2019). The Significance of Vitamin D Status in Breast Cancer: A State of the Science Review. *J Midwifery Womens Health*, 64(3), 276-288. doi:10.1111/jmwh.12968

Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., . . . Still, C. D. (2019). CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES – 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS. *Endocrine Practice*, 25(Supplement 2), 1-75. doi:10.4158/gl-2019-0406

Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., . . . Brethauer, S. (2013). Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society,

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

- and American Society for Metabolic & Bariatric Surgery. *Endocr Pract*, 19(2), 337-372. doi:10.4158/ep12437.g1
- Moyer, V. A. (2013). Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 158(9), 691-696. doi:10.7326/0003-4819-158-9-201305070-00603
- Moyer, V. A., & USPSTF. (2013). Screening for hiv: U.s. preventive services task force recommendation statement. *Annals of Internal Medicine*, 159(1), 51-60. doi:10.7326/0003-4819-159-1-201307020-00645
- Pazirandeh, S., & Burns, D. (2021, September 23). Overview of vitamin D. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/overview-of-vitamin-d>
- Ribeiro, H. G., Dantas-Komatsu, R. C. S., Medeiros, J. F. P., Carvalho, M. C. d. C., Soares, V. d. L., Reis, B. Z., . . . Silbiger, V. N. (2021). Previous vitamin D status and total cholesterol are associated with SARS-CoV-2 infection. *Clin Chim Acta*, 522, 8-13. doi:10.1016/j.cca.2021.08.003
- Ross, A. C., Manson, J. E., Abrams, S. A., Aloia, J. F., Brannon, P. M., Clinton, S. K., . . . Shapses, S. A. (2011). The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*, 96(1), 53-58. doi:10.1210/jc.2010-2704
- Sahota, O. (2014). Understanding vitamin D deficiency. In *Age Ageing* (Vol. 43, pp. 589-591). England.
- Sanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., & Nicholson, G. C. (2010). Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*, 303(18), 1815-1822. doi:10.1001/jama.2010.594
- Scott, M. G., Gronowski, A. M., Reid, I. R., Holick, M. F., Thadhani, R., & Phinney, K. (2015). Vitamin D: the more we know, the less we know. *Clin Chem*, 61(3), 462-465. doi:10.1373/clinchem.2014.222521
- Scragg, R., Stewart, A. W., Waayer, D., Lawes, C. M. M., Toop, L., Sluyter, J., . . . Camargo, C. A., Jr. (2017). Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. *JAMA Cardiol*, 2(6), 608-616. doi:10.1001/jamacardio.2017.0175
- Sempos, C. T., & Binkley, N. (2020). 25-Hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. *Public Health Nutr*, 23(7), 1153-1164. doi:10.1017/s1368980019005251
- Sempos, C. T., Heijboer, A. C., Bikle, D. D., Bollerslev, J., Bouillon, R., Brannon, P. M., . . . Binkley, N. (2018). Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. *Br J Clin Pharmacol*, 84(10), 2194-2207. doi:10.1111/bcp.13652
- Trivedi, D. P., Doll, R., & Khaw, K. T. (2003). Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ*, 326(7387), 469. doi:10.1136/bmj.326.7387.469

Disclaimer: These policies are clinical editing payment decisions for Blue Cross of Blue Shield of Michigan and do not apply to Blue Care Network of Michigan.

- Ul Afshan, F., Nissar, B., Chowdri, N. A., & Ganai, B. A. (2021). Relevance of vitamin D(3) in COVID-19 infection. *Gene reports*, 24, 101270-101270. doi:10.1016/j.genrep.2021.101270
- USPSTF. (2018). Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US preventive services task force recommendation statement. *JAMA*, 319(15), 1592-1599. doi:10.1001/jama.2018.3185
- USPSTF. (2021). Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*, 325(14), 1436-1442. doi:10.1001/jama.2021.3069
- Wallace, A. M., Gibson, S., de la Hunty, A., Lamberg-Allardt, C., & Ashwell, M. (2010). Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. *Steroids*, 75(7), 477-488. doi:10.1016/j.steroids.2010.02.012
- Wassenaar, E., O'Melia, A. M., & Mehler, P. S. (2018). Gynecologic Care for Adolescents and Young Women With Eating Disorders. *Obstet Gynecol*, 132(4), 1065-1066. doi:10.1097/aog.0000000000002903
- Weinstein, S. J., Purdue, M. P., Smith-Warner, S. A., Mondul, A. M., Black, A., Ahn, J., . . . Albanes, D. (2015). Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Int J Cancer*, 136(6), E654-664. doi:10.1002/ijc.29157
- Yuniati, T., Judistiani, R. T. D., Natalia, Y. A., Irianti, S., Madjid, T. H., Ghozali, M., . . . Setiabudiawan, B. (2019). First trimester maternal vitamin D, ferritin, hemoglobin level and their associations with neonatal birthweight: Result from cohort study on vitamin D status and its impact during pregnancy and childhood in Indonesia. *J Neonatal Perinatal Med*. doi:10.3233/npm-180043
- Zittermann, A., Pilz, S., & Berthold, H. K. (2019). Serum 25-hydroxyvitamin D response to vitamin D supplementation in infants: a systematic review and meta-analysis of clinical intervention trials. *Eur J Nutr*. doi:10.1007/s00394-019-01912-x

IX. Revision History

Effective Date	Summary
06/01/2022	Initial Policy Implementation